Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262170 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers
A Phase 1 study, sponsored by Rock Creek Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 109
- Enrollment target
NCT01262170 is a Phase 1 study that has completed, run by Rock Creek Pharmaceuticals. The registered enrollment target is 109 participants.
The verdict
NCT01262170, a Phase 1 study, has completed, sponsored by Rock Creek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke
Interventions
- DIETARY_SUPPLEMENT CigRx Lozenge
- OTHER Tobacco Lozenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262170
The ClinicalTrials.gov registry entry for NCT01262170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rock Creek Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CigRx Lozenge is the first listed.
NCT01262170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262170 about?
NCT01262170 is a clinical study titled "A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers". A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke
What is the current status of trial NCT01262170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2010-04. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01262170?
The interventions under investigation include: CigRx Lozenge (DIETARY_SUPPLEMENT), Tobacco Lozenge (OTHER).
Who is sponsoring clinical trial NCT01262170?
This trial is sponsored by Rock Creek Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.